Enzon Pharmaceuticals, Inc. (ENZN) Reports Q4 Loss of $0.10
Tweet
Share
E-mailGet Alerts ENZN Hot Sheet
Price: $4.35 --0%
Financial Fact:
Weighted average shares - diluted (in Shares): -88.33M
Today's EPS Names:
LGCY, UXIN, SCHL, More
Financial Fact:
Weighted average shares - diluted (in Shares): -88.33M
Today's EPS Names:
LGCY, UXIN, SCHL, More
Join SI Premium – FREE
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) reported Q4 EPS of ($0.10), versus ($0.16) reported last year. Revenue from royalties for the quarter came in at $9.8 million, versus $10.6 million reported last year.
For earnings history and earnings-related data on Enzon Pharmaceuticals, Inc. (ENZN) click here.
For earnings history and earnings-related data on Enzon Pharmaceuticals, Inc. (ENZN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and memory not a classic bubble, but future returns uncertain - strategist
- Stifel reports August 2026 client assets and revenue outlook
- SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
